May Health

Advancing novel treatment for women suffering from Polycystic Ovary Syndrome related infertility.

At a glance

Year of investment: 2024
Sector: Pharmaceuticals
Stage: Clinical development
Headquarters: Paris
CEO: Anne Morrissey
Trill Impact board representative: Nina Rawal, Bita Sehat (Board Observer)

Website

Business description

May Health is a clinical-stage medical device company committed to developing treatment options for women living with PCOS. The company is currently investigating its Ovarian Rebalancing™ treatment in clinical studies. Ovarian Rebalancing is a novel approach to PCOS-related fertility that has the potential to be a safe, straightforward option for activating natural ovulation.

May Health is led by a team of serial medtech and women’s health entrepreneurs and executives with extensive experience in product development, validation, and launch. The company was founded in 2017 by Sofinnova Partners’ medtech acceleration team, MD Start. May Health is headquartered in Paris.

“"For the millions of women living with PCOS, the physical and emotional impact of this condition are profound. From fertility challenges to emotional well-being and physical symptoms, women with PCOS need more viable treatment options. We are thankful to Trill Impact and Bpifrance for co-leading this financing round, and to Sofinnova Partners for their confidence in our team and for their support of our strategy to build a global Women’s Health company and to allow us to bring a solution for women with PCOS-related infertility issues.”

- Anne Morrissey, CEO of May Health

May Health's solution

Social/Environmental challenge

Polycystic ovary syndrome (PCOS) is a hormonal disorder affecting 1:10 women globally and is the leading cause of female infertility. PCOS is a lifelong challenge that goes beyond fertility issues and is associated with insulin resistance, Type 2 diabetes, increased risk of cardiovascular disease, endometrial cancer as well as mental health issues such as depression and anxiety.

SDG Contribution

Through its products, May Health aims to contribute to several of the SDGs:

SDG #3.7 and SDG #5.6
Ensure universal access to sexual and reproductive health-care services in accordance with ICPD and Beijing Platform for Action

SDG #3.4
By 2030, reduce by one third premature mortality from non-communicable diseases through prevention and treatment and promote mental health and well-being.

SDG #3.4.1
Reduce mortality rate attributed to cardiovascular disease, cancer, diabetes or chronic respiratory disease.

Latest news & insights

Press Release

13 maj 2024

Trill Impact Ventures co-leads USD 25 million series B financing round in May Health

Advancing novel treatment for women suffering from Polycystic Ovary Syndrome related infertility.

See all articles here